Ignite Creation Date:
2024-05-06 @ 5:36 PM
Last Modification Date:
2024-10-26 @ 2:32 PM
Study NCT ID:
NCT05366465
Status:
UNKNOWN
Last Update Posted:
2023-10-25
First Post:
2022-05-04
Brief Title:
Quality of Life and Participation of the Adult With Spinal Muscular Atrophy in France
Sponsor:
Hospices Civils de Lyon
Organization:
Hospices Civils de Lyon
Study Overview
Official Title:
Specificities of Quality of Life and Influence of Participation on the Quality of Life of the Adult With Spinal Muscular Atrophy in France a Cross-sectional Study
Status:
UNKNOWN
Status Verified Date:
2022-10
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
QOLSMA
Brief Summary:
Spinal muscular atrophy is a hereditary motorneuron disease caused by a mutation of the SMN1 gene which is at the origin of a progressive limb and axial motor deficiency It concerns 1200 individuals in France including 700 adults in 2018 The main objective of this study is to assess the quality of life of SMA patients in France
The secondary objectives are in one hand to compare the quality of life of SMA patients to a population of neuromuscular diseases patients And on the other hand to evaluate the determinants of participation and the impact of participation on quality of life in adult SMA patients
The secondary objectives are in one hand to compare the quality of life of SMA patients to a population of neuromuscular diseases patients And on the other hand to evaluate the determinants of participation and the impact of participation on quality of life in adult SMA patients
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None